

COVID-19 Seroprevalence Report 2020-08-20

COVID-19 Seroprevalence Report August 19, 2020

Samples collected from May 9 to June 18, 2020

1

Introduction

SARS-Cov-2 is a novel coronavirus first identified in Wuhan, Hubei province China in late 2019. It is responsible for a respiratory illness, coronavirus infection disease (COVID-19). Some people become extremely ill and can die from complications, while others experience mild symptoms or may not be aware of their infection at all. As of August 18th,2020 122,872 cases of COVID-19 have been reported in Canada, and 9,032 deaths. These statistics do not convey the true infection rate because some infections will not cause illness, others may not be severe enough for people to seek testing. Testing for SARS-Cov-2 antibodies is important to understand what proportion of the population have already been infected (the seroprevalence) and to monitor infection over the course of the pandemic. This information will improve mathematical models to predict the course of infection and inform public health policy.

Blood donors are reasonably representative of healthy Canadians between the ages of 17 and about 60. There are people are over 60 who donate blood, although there are fewer as age increases. There are blood collection sites in all large cities and many smaller urban centres in all provinces except Quebec but people in rural areas may have less opportunity to donate. Blood donations are not collected in the northern territories.

In partnership with the Canadian Immunity Task Force, Canadian Blood Services is testing samples left over from donations for SARS-Cov-2 antibodies. The objective is to inform public health policy and evaluate the impact on the blood supply. In this first report to the Canadian Immunity Task Force results from testing of blood donor samples collected between May 9 to June 18, 2020 are presented.

2

Methods

Blood donor eligibility

Before each donation blood donors must answer screening questions to ensure that they are in good health and do not have risk factors for infections that may be transmitted to blood recipients. There is no evidence that SARS-Cov-2 can be transmitted through blood transfusion, but it is important to ensure other donors and staff are safe while in the blood clinic. Donors are asked if they have had COVID-19 or been in contact with someone who has. They are deferred from donation for 2 weeks if they have been in contact with someone who was infected, and if they have had the infection deferral is for two weeks after symptoms disappear. Donors also have their temperature checked before they enter the clinic, and their hemoglobin level is checked before they can donate.

Blood samples

Just before a donor gives their blood donation, several small tubes of blood are collected for infectious disease and other testing. An extra sample is taken, called the retention sample, in case extra testing is required. Only about 20% of these retention samples are needed. For seroprevalence testing plasma from the 80% of retention samples not needed for operational testing was aliquoted and frozen at -20°C or colder, starting on May 9, 2020.

SARS-Cov-2 antibody testing

All plasma samples were tested using the Abbott Architect SARS-Cov-2 IgG assay (chemiluminescent microparticle immunoassay (CMIA)). This assay was assumed to have 92.7% (90.2-94.8%) sensitivity and 99.9% (99.4 – 100%) specificity (1). Testing was conducted at Canadian Blood Services in Ottawa.

Data management and analysis

All participant data were de-identified by the information technology team at Canadian Blood Services by providing a random identification number. Demographic variables were extracted from the Canadian Blood Services donor database (e.g. donation date, birth year, sex, Forward Sortation Area of residential postal code) and linked to the test data.. Information about the study was made available on the web-site in late June, prior to commencing testing. Donors were not informed of their results because confirmatory/supplemental testing was not carried out. This study was approved by the Canadian Blood Services Research Ethics committee.

Data management and analysis

De-identified data were analysed by the Canadian Blood Services Epidemiology & Surveillance Department. Because blood donors tend to live in areas close to a blood clinic there will be higher concentrations of donors in certain areas compared with the general population, and

Confidential (C)

3

lower concentrations in other areas. In order to make inference to the general population, weighting factors were applied based on the donor's residential Forward Sortation Area (FSA), age group and sex. Data were weighted based on Statistic Canada data (catalogue # 98-400-X2016008). For FSAs with few donors, several FSAs were combined, generally to include at least 500 donors. For data with no FSA recorded or if not in a province where blood is collected (0.21% of samples) weighting was based on FSA of the blood centre.

The seroprevalence was calculated as the number of positive samples divided by all samples tested. Ninety-five percent confidence intervals were calculated based on the binomial distribution (Exact method). The adjusted seroprevalence and confidence intervals present the weighted data adjusted for sensitivity and specificity of the assay using the Rogan-Gladen equation (2). Breakdowns of seroprevalence by province, sex and age groups were prepared, as well as for a selection of cities. Statistical comparisons between groups were carried out using logistic regression.

Results

As shown in Table 1, of 37,737 samples tested slightly over half were from male donors and are from all age groups although there tend to be more from older age groups. Just over half of donations were from Ontario, the next highest numbers of donations were Alberta and British Columbia. There were somewhat more donations tested from eastern Canada than Canadian Blood Services' usual collections because for logistic reasons samples from eastern Canada were stored starting about two weeks earlier than from the western provinces.

Table 2 shows the seroprevalence rates for all 9 provinces and for all of Canada (except Quebec and territories). The overall adjusted seroprevalence is 0.70%. The weighted percent positive was greater in females (p<0.05) but there were no significant differences between age groups (Figure 1).

Table 3 compares seroprevalence by province (See also Figure 2). The highest adjusted rate was in Ontario at 0.96% and the lowest in Newfoundland and Prince Edward Island. However, the numbers of samples in some provinces are small, hence wide confidence intervals. Using a logistic model with Ontario as the reference Ontario was higher than British Columbia and Alberta (p<0.01).

Table 4 shows the seroprevalence by cities which had sufficient numbers of samples to permit meaningful interpretation. The highest seroprevalence was observed in Ontario cities (Ottawa 1.29%, Toronto 1.07%).

4

Conclusion

The seroprevalence of SARS-Cov-2 was low in Canadian blood donors during May 9 to June 18, 2020 (less than 1%). It was slightly higher in Ontario compared with other provinces. There was slightly higher seroprevalence in females compared with males, but no difference between age groups. While the donation selection criteria ensure blood donors are healthy, caution should be exercised in extrapolating findings to all healthy adult Canadians because blood donors self-select to be blood donors, because in some areas access to a donation clinic may be limited and because there are fewer elderly donors.

Points for Interpretation

- 1. Blood donors are a healthy sub-set of the adult Canadian population. Important points to keep in mind with regard to representativeness of the sample are:
 - blood donors self-select to donate blood therefore those who choose not to donate blood for whatever reason are not included in the sample.
 - Blood donations are collected from people aged 17 years and older, however there are relatively few donations from elderly donors.
 - Blood donations are collected in larger cities and many smaller urban areas, but people in rural areas may be under-represented. Canadian Blood Services does not collect blood in the northern territories or the province of Quebec.
- 2. Data were weighted for age, sex and location to be more closely reflect the Canadian population. However, weighting of the data had only a modest impact on the seroprevalence estimate. For example, the unweighted seroprevalence for the full sample was 0.73%, and after weighting factors applied it was 0.75%, then after the weighted seroprevalence was adjusted for sensitivity and specificity, 0.70%.
- 3. The sensitivity and specificity of the Abbott assay were obtained from a report from the United Kingdom. The manufacturer indicates higher sensitivity and a second more recently released report form Denmark indicates it may be slightly lower.
- 4. The sensitivity and specificity of the assay are very good, but it is still possible that some true positives may be missed, and some positive results may be false. Confirmatory testing has not been performed. The seroprevalence was adjusted for sensitivity and specificity using a well-established mathematical formula. The Abbott assay used by Canadian Blood Services detects IgG antibodies to the SARS-CoV-2 nucleocapsid protein. IgG develops during infection but may not be present early in the course of infection. Donors are deferred if they have recent COVID_19 infection, but asymptomatic early stage infections may not be

Confidential (C)

5

The information provided herein may not be reproduced, transmitted or disclosed without the prior written approval of Canadian Blood Services. The information is provided "AS IS" and Canadian Blood Services makes no representations or warranties, express or implied, including with regards to the accuracy, reliability, validity or completeness of the information or its fitness for a particular purpose.

detected. In some rare cases, donors may have variable antibody responses to different binding sites on the SARS-CoV-2 virus (e.g. Spike, receptor binding domain of Spike, nucleocapsid protein).

- 5. The adjusted percent positive was statistically higher in females compared with males, but a spurious finding cannot be ruled out with a single sample.
- 6. In total, 38,638 samples were tested. Of these 901 (2.3 %) were a donation from donors who had been tested more than once during the sampling period. Most of these (98%) were apheresis donations which permit frequent donation. Three of these donations were positive on their first donation; there were no donations negative on their first donation and later positive, and none negative after a positive test. Repeat tested samples were excluded from the present analysis. Analysis is presented for the 37,737 first time tested samples of which most (95.6%) were from whole blood donations.
- 7. There were 0.21% of donations with an FSA in Quebec, the territories or missing. When compared with these donations excluded, there was no difference.

References

- The National SARS-Cov-2 Serologic Assay Evaluation Group. Head-to-head benchmark evaluation of the sensitivity and specificity of five immunoassays for SARS-Cov-2 serology on >1500 samples. Available at: <u>https://doi.org/10.6084/m9.figshare.12593288.v1.</u>
- 2. Lang Z, Reiczigel J. Confidence limits for prevalence of disease adjusted for estimated sensitivity and specificity. Preventive Veterinary Medicine. 2014:113;13-22.

6

	Number Tested	Percentage
Sex		
Female	17,694	46.89
Male	20,043	53.11
Age		
17-24	3,581	9.49
25-39	10,781	28.57
40-59	14,147	37.49
60+	9,228	24.45
Province		
British Columbia	4,962	13.15
Alberta	5,644	14.96
Saskatchewan	1,387	3.68
Manitoba	1,753	4.65
Ontario	19,839	52.57
New Brunswick	1,477	3.91
Nova Scotia	1,610	4.27
Prince Edward Island	448	1.19
Newfoundland	617	1.64
Total	37,737	

Table 1. Number and percentage Canadian	Blood Services donor sa	mples tested
---	-------------------------	--------------


Confidential (C)

7

	Unweighted				Adjusted	
	Number Tested	Number Positive	Percent Positive	95% Confidence Interval	Percent Positive	95% Confidence Interval
Sex						
Female	17,694	144	0.81	0.687, 0.957	0.81	0.667, 0.946
Male	20,043	131	0.65	0.547, 0.775	0.58	0.456, 0.705
Age						
17-24	3,581	30	0.84	0.566, 1.194	0.62	0.367, 0.873
25-39	10,781	76	0.70	0.556, 0.882	0.66	0.479, 0.849
40-59	14,147	103	0.73	0.595, 0.882	0.74	0.580, 0.906
60+	9,228	66	0.72	0.554, 0.909	0.70	0.524, 0.878
Total	37,737	275	0.73	0.645, 0.820	0.70	0.603, 0.790

Table 2. SARS-Cov-2 Seroprevalence by Sex and Age

Figure 1. SARS-Cov-2 seroprevalence by age groups



8

Confidential (C)

		Unw	A	Adjusted		
	Number Tested	Number Positive	Percent Positive	95% Confidence Interval	Percent Positive	95% Confidence Interval
British Columbia	4,962	29	0.58	0.392, 0.838	0.50	0.304, 0.694
Alberta	5,644	24	0.43	0.273, 0.632	0.37	0.182, 0.552
Saskatchewan	1,387	10	0.72	0.346, 1.322	0.46	0.067, 0.846
Manitoba	1,753	9	0.51	0.235, 0.972	0.56	0.160, 0.970
Ontario	19,839	189	0.95	0.822, 1.098	0.96	0.810, 1.113
New Brunswick	1,477	6	0.41	0.149, 0.882	0.26	0.000, 0.657
Nova Scotia	1,610	7	0.43	0.175, 0.894	0.36	0.000, 0.769
Prince Edward Island	448	0				
Newfoundland and Labrador	617	1	0.16	0.004, 0.900	0.29	0.000, 0.771
Total	37,737	275	0.73	0.645, 0.820	0.70	0.603, 0.790

Table 3. SARS-Cov-2 seroprevalence by province

Confidential (C)

9




Figure 2. Prevalence by provinces

		Unv	veighted	Adjusted		
	Number Tested	Number Positive	Percent Positive	95% Confidence Interval	Percent Positive	95% Confidence Interval
Vancouver	2,873	20	0.70	0.426, 1.073	0.60	0.328, 0.865
Calgary	2,069	10	0.48	0.232, 0.887	0.43	0.089, 0.772
Edmonton	2,043	8	0.39	0.169, 0.770	0.38	0.057, 0.704
Ottawa	1,975	18	0.91	0.541, 1.437	1.29	0.735, 1.836
Toronto	6,597	71	1.08	0.841, 1.356	1.07	0.827, 1.304

10

Confidential (C)

Appendix - Regional SARS-Cov-2 seroprevalence by sex and age

		Unweighted				Adjusted	
	Number Tested	Number Positive	Percent Positive	95% Confidence Interval	Percent Positive	95% Confidence Interval	
Sex							
Female	2,383	12	0.50	0.260, 0.878	0.42	0.166, 0.670	
Male	2,579	17	0.66	0.384, 1.053	0.59	0.287, 0.884	
Age							
17-24	390	0	-		-		
25-39	1,478	8	0.54	0.234, 1.064	0.53	0.122, 0.945	
40-59	1,772	15	0.85	0.475, 1.392	0.83	0.415, 1.238	
60+	1,322	6	0.45	0.167, 0.985	0.33	0.033, 0.636	
Total	4,962	29	0.58	0.392, 0.838	0.50	0.304, 0.694	

Table 1.1. British Columbia

11

Confidential (C)

	Unweighted				Ac	Adjusted	
	Number Tested	Number Positive	Percent Positive	95% Confidence Interval	Percent Positive	95% Confidence Interval	
Sex							
Female	2,802	14	0.50	0.273, 0.837	0.41	0.140, 0.687	
Male	2,842	10	0.35	0.169, 0.646	0.32	0.071, 0.568	
Age							
17-24	564	4	0.71	0.194, 1.806	0.48	0.000, 1.054	
25-39	1,725	6	0.35	0.128, 0.756	0.33	0.006, 0.658	
40-59	2,095	9	0.43	0.197, 0.814	0.41	0.081, 0.734	
60+	1,260	5	0.40	0.129, 0.924	0.29	0.000, 0.643	
Total	5,644	24	0.43	0.273, 0.632	0.37	0.182, 0.552	

Table 1.2. Alberta

12

Confidential (C)

		Unv	weighted		Adjusted	
	Number Tested	Number Positive	Percent Positive	95% Confidence Interval	Percent Positive	95% Confidence Interval
Sex						
Female	1,479	9	0.61	0.279, 1.152	0.61	0.183, 1.028
Male	1,661	10	0.60	0.289, 1.104	0.42	0.047, 0.787
Age						
7-24	319	0	-		-	
25-39	878	3	0.34	0.071, 0.995	0.16	0.000, 0.530
40-59	1,163	5	0.43	0.140, 1.000	0.25	0.000, 0.627
60+	780	11	1.41	0.706, 2.509	1.44	0.599, 2.271
Total	3,140	19	0.61	0.365, 0.943	0.51	0.232, 0.795

Table 1.3. Saskatchewan and Manitoba

13

Confidential (C)

	Unweighted				Ac	Adjusted	
	Number Tested	Number Positive	Percent Positive	95% Confidence Interval	Percent Positive	95% Confidence Interval	
Sex							
Female	9,119	105	1.15	0.943, 1.392	1.17	0.944, 1.405	
Male	10,720	84	0.78	0.626, 0.969	0.73	0.538, 0.925	
Age							
17-24	1,956	25	1.28	0.829, 1.881	1.09	0.643, 1.541	
25-39	5,604	55	0.98	0.740, 1.276	0.98	0.662, 1.289	
40-59	7,511	69	0.92	0.715, 1.161	0.99	0.734, 1.252	
60+	4,768	40	0.84	0.600, 1.141	0.85	0.580, 1.120	
Total	19,839	189	0.95	0.822, 1.098	0.96	0.810, 1.113	

Table 1.4. Ontario

14

Confidential (C)

Table 1.5. Atlantic Provinces

		Unweighted				Adjusted	
	Number Tested	Number Positive	Percent Positive	95% Confidence Interval	Percent Positive	95% Confidence Interval	
Sex							
Female	1,911	4	0.21	0.057, 0.535	0.26	0.000, 0.568	
Male	2,241	10	0.45	0.214, 0.819	0.30	0.000, 0.643	
Age							
17-24	352	1	0.28	0.007, 1.573	0.08	0.000, 0.558	
25-39	1,096	4	0.36	0.100, 0.932	0.31	0.000, 0.835	
40-59	1,606	5	0.31	0.101, 0.725	0.12	0.000, 0.412	
60+	1,098	4	0.36	0.099, 0.930	0.51	0.000, 1.012	
Total	4,152	14	0.34	0.184, 0.565	0.28	0.050, 0.509	

15

Confidential (C)